Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sims

Showing results (501-510 of 528) with videos related to

Pageof 53
Sort By:
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 22, 2012
Multicolored stain-free histopathology with coherent Raman imagingChristian W Freudiger, Rolf Pfannl, Daniel A Orringer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's diseaseAlette M Wessels, Christopher Lines, Robert A Stern, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2021
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening DataR E Amariglio, S A M Sikkes, G A Marshall, et al.
Clinical Laboratory Science : Journal of the American Society for Medical Technology|June 15, 2012
A professional development model for medical laboratory scientists working in the Core LaboratoryFaheem A Ali, Lila A Pulido, Melinda N Garza, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|December 2, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extensionJennifer A Zimmer, John R Sims, Cynthia D Evans, et al.
JAMA Neurology|March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical TrialsJennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
Molecular Psychiatry|March 14, 2019
Correction: Genetic risk for schizophrenia and psychosis in Alzheimer diseaseM A A DeMichele-Sweet, E A Weamer, L Klei, et al.
Pageof 53

Showing results (501-510 of 528) with videos related to

Sort By:
Pageof 53
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's diseaseSandar Aye, Gunilla Johansson, Christoph Hock, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 22, 2012
Multicolored stain-free histopathology with coherent Raman imagingChristian W Freudiger, Rolf Pfannl, Daniel A Orringer, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 13, 2020
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's diseaseAlette M Wessels, Christopher Lines, Robert A Stern, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
The Journal of Prevention of Alzheimer'S Disease|June 8, 2021
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening DataR E Amariglio, S A M Sikkes, G A Marshall, et al.
Clinical Laboratory Science : Journal of the American Society for Medical Technology|June 15, 2012
A professional development model for medical laboratory scientists working in the Core LaboratoryFaheem A Ali, Lila A Pulido, Melinda N Garza, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
The Journal of Prevention of Alzheimer'S Disease|December 2, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extensionJennifer A Zimmer, John R Sims, Cynthia D Evans, et al.
JAMA Neurology|March 10, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical TrialsJennifer A Zimmer, Paul Ardayfio, Hong Wang, et al.
Molecular Psychiatry|March 14, 2019
Correction: Genetic risk for schizophrenia and psychosis in Alzheimer diseaseM A A DeMichele-Sweet, E A Weamer, L Klei, et al.
Pageof 53